8-K: Xeris Biopharma Unveils Ambitious Long-Term Growth Strategy, Targeting Multi-Billion Dollar Revenue by 2035

Xeris Biopharma Holdings, Inc. outlined its long-term strategic vision and financial outlook at its first Analyst and Investor Day, projecting significant revenue growth driven by Recorlev and the pipeline asset XP-8121.

Summary

• Xeris Biopharma Holdings, Inc. hosted its first Analyst and Investor Day on June 3, 2025, to detail its strategy for sustainable growth and value creation.
• The company reaffirmed its 2025 total revenue guidance in the range of $260 million to $275 million and its commitment to remaining Adjusted EBITDA positive.
• Xeris projects total revenue of approximately $750 million by 2030, driven by growth across its current product portfolio, with Recorlev as a primary driver.
• By 2035, Recorlev's annual net revenue is anticipated to reach approximately $1 billion.
• XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, is expected to achieve peak net revenue of $1 billion to $3 billion.
• The company emphasizes its financial strength, enabling the self-funding of both nearand long-term growth without the need for additional capital raises.
• Strategic focus includes seizing current market opportunities for Recorlev, expanding its clinical role in broader hypercortisolism, and advancing XP-8121 through Phase 3 development towards a target 2030 approval.

Sentiment

Score: 8

Explanation: The document presents a highly optimistic and detailed long-term growth strategy with specific, ambitious financial targets. The reaffirmation of 2025 guidance and the explicit statement of being fully funded and not requiring additional capital raises contribute to a strong positive sentiment, indicating confidence in future performance and financial stability.

Positives

• Reaffirmed strong 2025 total revenue guidance of $260 million to $275 million and commitment to remaining Adjusted EBITDA positive.
• Projected significant long-term revenue growth, with total revenue expected to reach approximately $750 million by 2030.
• Recorlev is anticipated to achieve annual net revenue of approximately $1 billion by 2035, demonstrating its potential as a long-term growth engine.
• XP-8121, a Phase 3-ready asset for hypothyroidism, has a projected peak net revenue of $1 billion to $3 billion, indicating blockbuster potential.
• The company is positioned as a 'fully funded' biopharmaceutical company, expecting to self-fund its growth without raising additional capital.
• Xeris has a proven, experienced management team with a track record of operational excellence and successful product launches.
• Leverages proprietary XeriSol formulation technology and expertise in drug-device development, as demonstrated by Gvoke HypoPen.
• Strong commercial execution capabilities across rare and retail markets, with 14 consecutive quarters of +20% product revenue growth.

Risks

• The company's financial position and potential need for financing to fund product development programs or commercialization efforts.
• Uncertainty regarding whether its products will achieve and maintain market acceptance in a competitive business environment.
• Reliance on third-party suppliers, including single-source suppliers, for manufacturing and components.
• Reliance on third parties to conduct clinical trials for its product candidates.
• The ability of its product candidates to compete successfully with existing and new drugs.
• The ability of its collaborators to protect its intellectual property and proprietary technology.
• General macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs, and market volatility.

Future Outlook

Xeris projects a strong growth trajectory, with total revenue expected to reach approximately $750 million by 2030. Beyond that, the company anticipates Recorlev's annual net revenue to hit $1 billion by 2035, and XP-8121, upon approval, is projected to achieve peak net revenue between $1 billion and $3 billion, positioning Xeris as a multi-billion dollar enterprise.

Management Comments

• John Shannon, Chief Executive Officer, stated: "We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achievements have positioned us to take the next bold step in our journey of growth and transformation. We are excited to share our vision for the future—one that builds on our successes, leverages our capabilities, and propels us toward making an even greater impact delivering meaningful solutions for patients."

Industry Context

Xeris Biopharma operates within the endocrinology therapeutic area, focusing on both rare diseases like Cushing's syndrome with Recorlev and widespread chronic conditions such as hypothyroidism with its pipeline asset XP-8121. The company's strategy to expand Recorlev's market by increasing awareness of broader hypercortisolism impacts (e.g., in stubborn diabetes) aligns with a trend of identifying and treating underlying endocrine imbalances in common metabolic disorders. The development of XP-8121 as a once-weekly subcutaneous injection for hypothyroidism addresses a significant unmet need for improved patient convenience and consistent biochemical control, differentiating it from existing daily oral therapies and reflecting an industry shift towards enhanced drug delivery methods for chronic conditions.

Comparison to Industry Standards

• XP-8121's projected peak net revenue of $1 billion to $3 billion positions it as a potential 'blockbuster' drug, a term commonly used in the pharmaceutical industry for products generating over $1 billion in annual sales, indicating significant market potential.
• The company's focus on addressing 'unmet medical needs' in both rare diseases (Cushing's syndrome) and widespread conditions (hypothyroidism) is a common and effective strategy for biopharmaceutical companies aiming for diversified revenue streams and broader market impact.
• The development of a once-weekly subcutaneous injection for hypothyroidism (XP-8121) aims to improve patient adherence and outcomes, a key differentiator in a market largely dominated by daily oral levothyroxine, and aligns with industry efforts to enhance patient convenience and therapeutic efficacy.
• Xeris's stated ability to self-fund its nearand long-term growth without additional capital raises is a strong indicator of financial health and operational efficiency, distinguishing it from many smaller biopharmaceutical companies that frequently rely on dilutive financing rounds.

Stakeholder Impact

• Shareholders/Investors: Potential for increased shareholder value due to strong projected revenue growth, commitment to positive Adjusted EBITDA, and the company's self-funded status, reducing dilution risk.
• Patients: Positive impact through the development and commercialization of innovative therapies (Recorlev, XP-8121) addressing serious unmet medical needs in Cushing's syndrome and hypothyroidism, aiming to improve patient experience and clinical outcomes.
• Employees: Potential for growth and stability within the company as the product portfolio expands and long-term strategic goals are pursued.
• Healthcare Professionals: New and potentially transformative treatment options that could simplify patient management and improve outcomes for complex endocrine disorders.

Next Steps

• Continue to invest heavily in Recorlev's promotional footprint, expand patient support services, and generate incremental data to seize current market opportunities.
• Expand Recorlev's clinical role in the broader hypercortisolism market, including management in patients with additional secondary comorbidities like stubborn diabetes.
• Advance research to inform marketplace testing protocols and guideline development for hypercortisolism.
• Ensure sustained long-term value of Recorlev through potential expansion into new indications, differentiated delivery modalities, and synergistic combination therapies.
• Execute the Phase 3 pivotal study for XP-8121, with study start targeted for 2026, last subject out in 2028, topline results in 2029, and NDA approval targeted for 2030.

Key Dates

Recommendation

Keywords

Biopharma, Pharmaceuticals, Endocrinology, Cushing's Syndrome, Hypercortisolism, Hypothyroidism, Recorlev, XP-8121, XERS, Drug Development, Clinical Trials, Rare Disease, Metabolic Disorders, Glucagon, Gvoke, Keveyis, XeriSol, XeriJect